The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension
Open accessAbstract
Background—Few treatments are available for isolated pulmonary hypertension (PHT), which has a high morbidity and mortality. This trial was designed to assess the hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with PHT, in which local overproduction of endothelin-1 (ET-1) is thought to play a pathogenic role. Methods and Results—An open-label, dose-ranging study was performed in 7 female patients with primary PHT (n=5) or isolated PHT associated with limited scleroderma (n=2). Infusions of 50, 150, and 300 mg were administered at 2-hour intervals, and the hemodynamic responses were measured. Bosentan caused a dose-dependent fall in total pulmonary resistance (−20.0±11.0%,P=0.01) and mean pulmonary artery pressure (−10.6±11.0%,P>0.05). However, there was also a fall in the systemic vascular resistance (−26.2±12.8%,P<0.005) and mean arterial pressure (−19.8±14.4%,P<0.001). There was a slight increase in cardiac index (15±12%,P>0.05) and a dose-dependent rise in ET-1 but no significant change in other hemodynamic variables, gas exchange, or other vasoactive mediators. Conclusions—Intravenous bosentan is a potent but nonselective pulmonary vasodilator at the doses tested, even in patients resistant to inhaled nitric oxide. Transient increases in plasma ET-1 were observed, consistent with a blockade of endothelial ET B receptors. Systemic hypotension and other significant events during the study indicate that its intravenous use in patients with severe PHT may be limited. Implications for future trial design and studies of chronic oral treatment are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension
PEPKEZABA, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)92033-x · Cited by 1,055
Cited by
Channick, R. N., Simonneau, G., Sitbon, O., Robbins, I. M., Frost, A., Tapson, V. F., Badesch, D. B., Roux, S., Rainisio, M., Bodin, F., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06250-x · Cited by 1,534
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Vasospasm, its Role in the Pathogenesis of Diseases with Particular Reference to the Eye
Flammer, J., Pache, M., & Resink, T. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(00)00028-8 · Cited by 382
Oka, M., Homma, N., Taraseviciene-Stewart, L., Morris, K. G., Kraskauskas, D., Burns, N., Voelkel, N. F., & McMurtry, I. F. (2007) · Circulation Research · doi:10.1161/01.res.0000261658.12024.18 · Cited by 331
Metadata
- Authors
- Williamson, D. J., Wallman, L. L., Jones, R., Keogh, A. M., Scroope, F., BEd, Penny, R., Weber, C., & Macdonald, P. S.
- Venue
- Circulation
- Published
- 2000-07-25
- Volume
- 102
- Issue
- 4
- Pages
- 411-418
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1992989380
- Cited by
- 185
- References
- 1
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension. https://app.cochat.ai/papers/10.1161/01.cir.102.4.411
- The paper
- Williamson, D. J., Wallman, L. L., Jones, R., Keogh, A. M., Scroope, F., BEd, Penny, R., Weber, C., & Macdonald, P. S. (2000). Hemodynamic Effects of Bosentan, an Endothelin Receptor Antagonist, in Patients With Pulmonary Hypertension. Circulation. https://doi.org/10.1161/01.cir.102.4.411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.